Table 3.
Summary of pharmacokinetic data for vancomycin 750 mg i.v. every 12 h
| Patient profile | Cmax(mg l−1) | t1/2(β) (h) | AUC0–12(mg h l−1) | AUC0–∞(mg h l−1) | Cl (l h−1) | Vss(l) | F12 (%) |
|---|---|---|---|---|---|---|---|
| 1A | 67.8 | 7.8 | 243.4 | 344.0 | 2.2 | 20.3 | 71 |
| 1B | 55.0 | 25.2 | 406.7 | 1.8 | 66.5 | NA | |
| 2A | 42.9 | 9.7 | 210.6 | 362.5 | 2.1 | 27.5 | 58 |
| 2B | 43.4 | 18.3 | 318.1 | 2.4 | 57.1 | NA | |
| 3A | 47.2 | 6.2 | 196.8 | 265.6 | 2.8 | 22.8 | 74 |
| 3B | 47.2 | 22.6 | 367.6 | 2.0 | 64.7 | NA | |
| 4B | 36.3 | 11.8 | 243.9 | 3.1 | 51.6 | NA | |
| 5A | 54.0 | 13.5 | 243.6 | 509.3 | 1.5 | 27.1 | 48 |
| 6B | 49.0 | 17.1 | 300.8 | 2.5 | 56.3 | NA | |
| 7B | 53.8 | 22.1 | 350.1 | 2.1 | 62.9 | NA | |
| 8A | 39.8 | 10.9 | 190.6 | 344.9 | 2.2 | 31.8 | 55 |
| 8B | 44.9 | 38.3 | 283.8 | 2.6 | 136.7 | NA | |
| 9B | 32.6 | 6.0 | 171.9 | 4.4 | 29.9 | NA | |
| 10A | 27.1 | 11.5 | 115.6 | 205.6 | 3.6 | 53.4 | 56 |
| 10B | 39.6 | 12.8 | 293.4 | 2.6 | 36.9 | NA | |
| Mean ± SD | – | 15.6 ± 8.7 | – | – | 2.5 ± 0.7 | 49.7 ± 29.1 | 60 ± 10 |
Patient profile each separate occasion that pharmacokinetics were studied (e.g. 1B is second occasion for patient 1). Cmax, Maximum vancomycin plasma concentration; t1/2(β) elimination half life; AUC0−12, areas under the curve for study period; AUC0–∞, area under the curve extrapolated to infinity; CL, total body clearance; Vss, volume of distribution at steady state; F12, fraction of vancomycin eliminated within dosing interval of initial or first dose (Profile A only); NA, not applicable.